Larson Financial Group’s Iterum Therapeutics ITRM Stock Holding History

Larson Financial Group’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13	Closed	-$20	–	2462
2024 Q1	$20	Hold	13	–	–	﹤0.01%	1772
2023 Q4	$26	Hold	13	–	–	﹤0.01%	1768
2023 Q3	$10	Hold	13	–	–	﹤0.01%	1698
2023 Q2	$14	Hold	13	–	–	﹤0.01%	1555
2023 Q1	$13	Hold	13	–	–	﹤0.01%	1536
2022 Q4	$11	Hold	13	–	–	﹤0.01%	1496
2022 Q3	$0	Hold	13	–	–	﹤0.01%	1345
2022 Q2	$0	Hold	13	–	–	﹤0.01%	1242
2022 Q1	$0	Hold	13	–	–	﹤0.01%	1107
2021 Q4	$0	Hold	13	–	–	﹤0.01%	1125
2021 Q3	$0	Hold	13	–	–	﹤0.01%	915
2021 Q2	$0	Hold	13	–	–	﹤0.01%	874
2021 Q1	$0	Buy	+13	New	+$309	﹤0.01%	885

Other funds holding ITRM

Apollon Financial Mount Pleasant, South Carolina $848M AUM 27.31% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

KFS

Kelly Financial Services Braintree, Massachusetts $467M AUM 21.13% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BBPWM

Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return

Larson Financial Group's ITRM Position: Q2 2024 in Review

Larson Financial Group sold out of Iterum Therapeutics (ITRM) in Q2 2024, closing a stake of 13 shares — an estimated $20 sold.

Larson Financial Group first reported a position in ITRM in Q1 2021 and held it in 13 quarters. The position peaked at $26 in Q4 2023. 15 funds tracked by Wall St. Rank hold ITRM as of Q2 2024.

Larson Financial Group reported no remaining Iterum Therapeutics position as of Q2 2024 after selling out during the quarter.
Larson Financial Group sold 13 Iterum Therapeutics shares in Q2 2024, an estimated $20.
Larson Financial Group first reported a position in Iterum Therapeutics in Q1 2021 and held it in 13 quarters.
Larson Financial Group's Iterum Therapeutics position peaked at $26 in Q4 2023.
15 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2024.

Based on Larson Financial Group's 13F filing for Q2 2024, filed 2 Aug 2024.